GNCA Genocea Biosciences Inc

Price (delayed)

$1.96

Market cap

$111.75M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.54

Enterprise value

$69.97M

Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or ...

Highlights
GNCA's EPS has soared by 61% YoY and by 38% QoQ
Genocea Biosciences's debt has decreased by 23% YoY and by 2% QoQ
Genocea Biosciences's equity has surged by 130% QoQ but it has decreased by 50% YoY
The revenue has plunged by 67% from the previous quarter and by 50% YoY
GNCA's gross profit has dropped by 67% since the previous quarter and by 50% year-on-year

Key stats

What are the main financial stats of GNCA
Market
Shares outstanding
57.02M
Market cap
$111.75M
Enterprise value
$69.97M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
26.31
Price to sales (P/S)
294.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
154.46
Earnings
Revenue
$453,000
EBIT
-$34.52M
EBITDA
-$33.18M
Free cash flow
-$44.63M
Per share
EPS
-$0.54
Free cash flow per share
-$0.66
Book value per share
$0.07
Revenue per share
$0.01
TBVPS
$1.14
Balance sheet
Total assets
$77.38M
Total liabilities
$73.33M
Debt
$19.25M
Equity
$4.06M
Working capital
$48.08M
Liquidity
Debt to equity
4.75
Current ratio
4.24
Quick ratio
4.11
Net debt/EBITDA
1.26
Margins
EBITDA margin
-7,325.2%
Gross margin
100%
Net margin
-7,910.4%
Operating margin
-10,909.7%
Efficiency
Return on assets
-39.2%
Return on equity
-409.5%
Return on invested capital
-168.1%
Return on capital employed
-55.2%
Return on sales
-7,619.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GNCA stock price

How has the Genocea Biosciences stock price performed over time
Intraday
-3.45%
1 week
-3.45%
1 month
-12.89%
1 year
-37.18%
YTD
-19.01%
QTD
-16.24%

Financial performance

How have Genocea Biosciences's revenue and profit performed over time
Revenue
$453,000
Gross profit
$453,000
Operating income
-$49.42M
Net income
-$35.83M
Gross margin
100%
Net margin
-7,910.4%
Genocea Biosciences's net margin has shrunk by 151% QoQ and by 75% YoY
The company's operating margin has shrunk by 125% YoY
The revenue has plunged by 67% from the previous quarter and by 50% YoY
GNCA's gross profit has dropped by 67% since the previous quarter and by 50% year-on-year

Growth

What is Genocea Biosciences's growth rate over time

Valuation

What is Genocea Biosciences stock price valuation
P/E
N/A
P/B
26.31
P/S
294.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
154.46
GNCA's EPS has soared by 61% YoY and by 38% QoQ
The stock's P/B is 135% above its 5-year quarterly average of 11.2 but 20% below its last 4 quarters average of 32.8
Genocea Biosciences's equity has surged by 130% QoQ but it has decreased by 50% YoY
GNCA's P/S is 79% above its last 4 quarters average of 163.9
The revenue has plunged by 67% from the previous quarter and by 50% YoY

Efficiency

How efficient is Genocea Biosciences business performance
GNCA's ROS has shrunk by 150% QoQ and by 72% YoY
Genocea Biosciences's ROE has plunged by 93% YoY but it has increased by 7% from the previous quarter
The ROA has soared by 53% YoY and by 25% from the previous quarter
The ROIC has grown by 16% from the previous quarter

Dividends

What is GNCA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GNCA.

Financial health

How did Genocea Biosciences financials performed over time
Genocea Biosciences's total assets is 6% more than its total liabilities
The company's total liabilities has surged by 126% YoY but it fell by 11% QoQ
Genocea Biosciences's total assets has soared by 91% YoY but it has decreased by 8% from the previous quarter
Genocea Biosciences's equity has surged by 130% QoQ but it has decreased by 50% YoY
The debt to equity has dropped by 57% since the previous quarter but it has soared by 52% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.